SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-164449
Filing Date
2024-06-20
Accepted
2024-06-20 16:08:01
Documents
13
Period of Report
2024-06-18
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d856385d8k.htm   iXBRL 8-K 34594
  Complete submission text file 0001193125-24-164449.txt   156706

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA virx-20240618.xsd EX-101.SCH 2838
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE virx-20240618_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE virx-20240618_pre.xml EX-101.PRE 11253
16 EXTRACTED XBRL INSTANCE DOCUMENT d856385d8k_htm.xml XML 3632
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 241056256
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)